PSAdtProstate Specific Antigen Doubling Time
References in periodicals archive ?
Postulating an exponential rather than linear PSA increase and a PSADT of <12 months in these men presenting with PSA>100 at the age of 50 years, it is clear that to detect cancer at a potentially curable stage (PSA <20 ng/ml) would have required PSA testing at the age of 40, or even earlier.
The median pre-treatment PSADT for the 21 evaluable patients was 6.
Patients with a rapid PSADT (<8 months) are at risk for developing earlier metastases.
Patients with a negative PSAdt (non-rising PSA before abiraterone) had the longest median survival of 18 months (95% CI 9.
PSADT is currently considered to be one of the best predictors of clinical outcome in patients with PSA recurrence following primary therapy.
PSA = prostate-specific antigen; PSADT = PSA doubling time; CRPC = castrate-resistant prostate cancer.
Investigators found that a combination of Provenge and Avastin extended PSADT of the 21 evaluable patients by more than 85 percent from 6.
A little over a quarter of the respondents felt that PSAdt was the more important factor, while 3% of respondents felt that absolute PSA was the more important factor.
PSADT is the time it takes for the PSA value to double.
PSA = prostate-specific antigen; PSADT = prostate-specific antigen doubling time; HRPC = hormone-refractory prostate cancer
PSADT is the time it takes for the prostate-specific antigen (PSA) value to double.